Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab in Resectable Melanoma
NCT06190951Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Countries
- 8
01
Overview
A Phase 2 trial of fianlimab in melanoma, sponsored by Regeneron Pharmaceuticals. Started Sep 2024; status: active, not recruiting.
02
Drugs
fianlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06190951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190951.